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Fig. S3 | Comparison of enrichment performance between HUNTER and TAILS.
(a) Number of N termini identified from 10,000 to 1,000,000 HeLa cells with HUNTER (orange) and TAILS (green) enrichment methods. Datapoints represent technical replicates (n=4 for each condition, except n=3 for 1M HeLa cells from TAILS), middle lines indicate the mean, and error bars indicate SD. (b) Comparison of termini identification in 500K HeLa cells duplicates from two different enrichment methods and within the two enrichment methods. First replica in orange color, second replica in green, and overlap in yellow. (c) Peptide length distribution in identified termini from 10,000 to 1,000,000 HeLa cells with HUNTER (orange) and TAILS (green). (d) Molecular weight distribution in identified termini from 10,000 to 1,000,000 HeLa cells with HUNTER (orange) and TAILS (green). (e) Peptide gravy score distribution in identified termini from 10,000 to 1,000,000 HeLa cells with HUNTER (orange) and TAILS (green). (f) Protein gravy score distribution in identified proteins from 10,000 to 1,000,000 HeLa cells with HUNTER (orange) and TAILS (green). Termini are displayed according to their position on the genome encoded sequence of proteins involved in the complement pathway. Complement proteins are known to be proteolytically cleaved and several fragments with defined start sites are known. Termini matching these start sites are highlighted by grey background and also added to the pathway diagram. Log2 fold changes of termini abundance at diagnosis (D0) and after induction chemotherapy (D29) are color coded from blue (<-2) to red (>2) and visualized for blood plasma (BP) and bone marrow interstitial fluid (BM) next to the respective terminus identified by HUNTER. Note: white blood cell abbreviated as WBC; bone marrow abbreviated as BM; minimal residual disease abbreviated as MRD; D0 is before treatment whereas D29 is after treatment.
